Invesco Ltd. Has $13.86 Million Holdings in Haleon PLC Sponsored ADR $HLN

Key Points

• Invesco Ltd. has reduced its stake in Haleon PLC by 17.0%, owning a total of 1,346,966 shares after selling 275,550 shares during the first quarter.
• BNP Paribas upgraded Haleon from a "neutral" to an "outperform" rating with a price target of $13.40, while Morgan Stanley raised its rating to "overweight".
• Haleon announced a semi-annual dividend of $0.0555 per share, increasing from the previous dividend of $0.05, reflecting a positive change in their dividend strategy.

Invesco Ltd. decreased its stake in Haleon PLC Sponsored ADR (NYSE:HLN - Free Report) by 17.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,346,966 shares of the company's stock after selling 275,550 shares during the period. Invesco Ltd.'s holdings in Haleon were worth $13,860,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in HLN. Bartlett & CO. Wealth Management LLC raised its stake in Haleon by 135.9% during the 1st quarter. Bartlett & CO. Wealth Management LLC now owns 2,588 shares of the company's stock valued at $27,000 after acquiring an additional 1,491 shares in the last quarter. Opal Wealth Advisors LLC bought a new stake in Haleon during the 1st quarter valued at $29,000. Deutsche Bank AG raised its stake in Haleon by 267.8% during the 1st quarter. Deutsche Bank AG now owns 3,126 shares of the company's stock valued at $32,000 after acquiring an additional 2,276 shares in the last quarter. Continuum Advisory LLC raised its stake in Haleon by 152.4% during the 1st quarter. Continuum Advisory LLC now owns 4,753 shares of the company's stock valued at $49,000 after acquiring an additional 2,870 shares in the last quarter. Finally, Alpine Bank Wealth Management bought a new stake in Haleon during the 1st quarter valued at $56,000. Institutional investors own 6.67% of the company's stock.

Haleon Stock Up 1.0%

Shares of HLN stock traded up $0.10 on Wednesday, reaching $9.73. 5,124,726 shares of the company's stock traded hands, compared to its average volume of 12,771,431. Haleon PLC Sponsored ADR has a 12-month low of $8.86 and a 12-month high of $11.42. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.63 and a current ratio of 0.87. The company has a market capitalization of $43.61 billion, a P/E ratio of 24.96, a price-to-earnings-growth ratio of 2.86 and a beta of 0.23. The business's 50 day moving average price is $9.89 and its two-hundred day moving average price is $10.21.

Haleon Increases Dividend

The company also recently announced a semi-annual dividend, which will be paid on Thursday, September 18th. Shareholders of record on Friday, August 15th will be given a $0.0555 dividend. This represents a yield of 190.0%. The ex-dividend date of this dividend is Friday, August 15th. This is an increase from Haleon's previous semi-annual dividend of $0.05. Haleon's payout ratio is currently 28.21%.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. BNP Paribas Exane raised Haleon from a "neutral" rating to an "outperform" rating and set a $13.40 target price on the stock in a research note on Tuesday, May 27th. Morgan Stanley upgraded Haleon from an "equal weight" rating to an "overweight" rating and set a $11.25 price target on the stock in a research report on Friday, May 9th. BNP Paribas upgraded Haleon to a "strong-buy" rating in a research report on Tuesday, May 27th. Barclays restated an "overweight" rating on shares of Haleon in a report on Tuesday, May 6th. Finally, Wall Street Zen cut Haleon from a "buy" rating to a "hold" rating in a report on Saturday, July 12th. Two investment analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $12.33.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.